Hepatitis C Virus Treatment (eBook)
VII, 75 Seiten
Springer Singapore (Verlag)
978-981-10-2416-0 (ISBN)
This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects.
Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.Prof. Kazuaki Chayama
This book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.
Prof. Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University
PrefaceThe first generation protease inhibitor Telaprevir and the emergence of antiviral resistanceFeatures of the second wave of the first generation protease inhibitors: effect and toleranceEffects and resistance risks of combination treatment with Daclatasvir + Asunaprevir: the first approved oral agent without IFN and ribavirinResistance features of NS5A inhibitors and methods for detectionDetection of naturally occurring variants with resistance features against antiviral drugsIncidence and characteristics of naturally occurring resistant strainsCharacteristics and resistance profiles of polymerase inhibitorsEmerging antivirals in the future
| Erscheint lt. Verlag | 1.11.2016 |
|---|---|
| Zusatzinfo | VII, 75 p. 23 illus., 14 illus. in color. |
| Verlagsort | Singapore |
| Sprache | englisch |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hepatologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Naturwissenschaften ► Biologie | |
| Technik | |
| Schlagworte | antibacterial drug resistance • Chronic liver disease • DAA • Direct Acting Antiviral Agents • HCV • hepatology • immunity • Infection • Interferon • Polymerase Inhibitor • Protease inhibitor • Resistance Mutations • Ribavirin • Telaprevir |
| ISBN-10 | 981-10-2416-2 / 9811024162 |
| ISBN-13 | 978-981-10-2416-0 / 9789811024160 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 4,1 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
